230 related articles for article (PubMed ID: 36150262)
1. Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon.
Matni M; Yamout B; Koussa S; Khamis C; Fleifel L; Sharifi S; Mohamed O
Mult Scler Relat Disord; 2022 Nov; 67():104169. PubMed ID: 36150262
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation of Cladribine Tablets in Patients With High Disease Activity-Relapsing-Remitting Multiple Sclerosis in the Kingdom of Saudi Arabia.
Bohlega S; Elboghdady A; Al-Johani A; Mahajan K; Mughari MK; Al-Saqa'aby M; Mohamed O; Alarieh R; Al Malik Y
Value Health Reg Issues; 2021 Sep; 25():189-195. PubMed ID: 34425468
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.
Michels RE; de Fransesco M; Mahajan K; Hengstman GJD; Schiffers KMH; Budhia S; Harty G; Krol M
Appl Health Econ Health Policy; 2019 Dec; 17(6):857-873. PubMed ID: 31444659
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; Trillo JL; Rubio-Terrés C; Rubio-Rodríguez D; Polanco A; Torres C
Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):295-303. PubMed ID: 31220959
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Pinheiro B; Guerreiro R; Costa J; Miguel LS
J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
[No Abstract] [Full Text] [Related]
7. Cladribine tablets are a cost-effective strategy in high-disease activity relapsing multiple sclerosis patients in Iran.
Ayati N; Fleifel L; Sharifi S; Sahraian MA; Nikfar S
Curr J Neurol; 2021 Jul; 20(3):146-153. PubMed ID: 38011415
[No Abstract] [Full Text] [Related]
8. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
Mankinen P; Lundström T; Soini E; Sumelahti ML; Ruutiainen J; Niskala U; Järvinen E
Adv Ther; 2020 Feb; 37(2):800-818. PubMed ID: 31873868
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis].
Avxentyev NA; Davydovskaya MV; Makarova YV; Frolov MY; Klabukova DL
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):30-36. PubMed ID: 34481433
[TBL] [Abstract][Full Text] [Related]
10. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain.
Ginestal R; Rubio-Terrés C; Morán OD; Rubio-Rodríguez D; Los Santos H; Ordoñez C; Sánchez-Magro I
J Comp Eff Res; 2023 Feb; 12(2):e220193. PubMed ID: 36705064
[No Abstract] [Full Text] [Related]
12. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
Brownlee WJ; Haghikia A; Hayward B; Waser N; Kayaniyil S; Khan Z; Duncan J; Millar S; Harty GT
Mult Scler Relat Disord; 2023 Aug; 76():104791. PubMed ID: 37343465
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
[TBL] [Abstract][Full Text] [Related]
14. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Lambe T; Duarte R; Mahon J; Nevitt S; Greenhalgh J; Boland A; Beale S; Kotas E; McEntee J; Pomeroy I
Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
[TBL] [Abstract][Full Text] [Related]
16. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
Alroughani R; Al-Hashel J; Ahmed SF
Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
[TBL] [Abstract][Full Text] [Related]
17. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
[No Abstract] [Full Text] [Related]
18. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
